ІНВАЗІЙНИЙ ФРОНТ КАРЦИНОМ: МОРФОЛОГІЧНІ ТА МОЛЕКУЛЯРНІ ОСОБЛИВОСТІ, АСОЦІАЦІЯ З ПРОГРЕСУВАННЯМ ПУХЛИННОГО РОСТУ
Ключові слова:
інвазійний фронт пухлини, інвазія, адгезія, міграція, молекулярні механізми, пухлинне брунькування (tumor budding), діагностичне і прогностичне значення.Анотація
Метою огляду є аналіз сучасних наукових відомостей щодо структурних
і функціональних особливостей інвазійного фронту пухлин як зони активного формування інвазійного та метастатичного фенотипу пухлинних клітин (ПК) на кордоні з прилеглою сполучною тканиною. Показана складність
і взаємнозумовленість молекулярно-генетичних, біохімічних і цитоморфологічних змін ПК, асоційованих з активацією їхньої інвазії — кардинального
етапу прогресування пухлинного процесу. Важливою морфологічною характеристикою інвазійного фронту пухлин є наявність кластерів ПК з фенотипом пухлинного брунькування, який розглядають як маркер між- та інтрапухлинної гетерогенності та морфологічний критерій для оцінки агресивності пухлин епітеліального генезу.
Посилання
Vasiliev YM. Reorganizations of molecular morphology of epithelial and conjunctive tissue cells in normal morphogenesis and carcinogenesis. Biochemistry (Moscow) 2008; 73 (5): 656–60 (in Russian).
Chekhun VF, Sherban SD, Savtsova ZD. Tumor heterogeneity — dynamical state. Oncology 2012; 14 (1): 4–12 (in Russian).
Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013; 501: 338–45.
Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010; 1805 (1): 105–17.
Gerashchenko TS. Intra-tumor morphological heterogeneity of breast cancer and its relation to the expression of drug stability. Thesis of MD. Tomsk 2017. 24 p.
Yang YL, Chu JY, Wang MR. Tumor genetic heterogeneity. Yi Chuan 2013; 35 (1): 1–9.
Ma N. Epithelial plasticity: a common theme in embryonic and cancer cells. Science 2013. doi: 10.1126/science.1234850.
Wu MJ, Chen YS, Kim MR, Chang CJ. Regulation of epithelial plasticity and cancer stemness via microRNAs. J Mol Genet Med 2016; 10: 212. doi:10.4172/1747–0862.1000212.
Galván J A, Zlobec I, Wartenberg M, et al. Expression of Ecadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer. Br J Cancer 2015; 112 (12): 1944–50.
Hu Z, Sun R, Curtis C. A population genetics perspective on the determinants of intra-tumor heterogeneity. Biochim Biophys Acta 2017; 1867 (2): 109–26.
Paterson EL, Kazenwadel J, Bert AG, et al. Down-regulation of the miRNA-200 family at the invasive front of colorectal
cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia 2013; 15: 180–91.
Bryne M, Boysen M, Alfsen CG, et al. The invasive front of carcinomas. The most important area for tumour prognosis? Anticancer Res 1998; 18 (6B): 4757–64.
Berezhnaya NM, Chekhun VF. Physiological system of conjunctive tissue and oncogenesis. II. Extracellular matrix and metastasis. Oncology 2016; 18 (3): 164–76 (in Russian).
Bronsert P, Enderle-Ammour K, Bader M, et al. Cancer cell invasion and EMT marker expression — a three-dimensional study of the human cancer-host interface. J Pathol 2014; 234: 410–22.
Grigore AD, Jolly MK, Jia D, et al. Tumor budding: the name is EMT. Partial EMT. J Clin Med 2016; 5 (5): 51. doi: 10.3390/jcm5050051.
Niwa Y, Yamada S, Koike M, et al. Epithelial to mesenchymal transition correlates with tumor budding and predicts prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2014; 110 (6): 764–9.
Anichkov NM. Tumor invasion. Stages of invasion of tumor cells. http:meduniver.com/Medical/gistologia/1051.html
MedUniver.
Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010; 316 (8): 1324–3.
Osinsky S, Vaupel P. Tumor microphysiology. Kiev, Naukova Dumka 2009. 256 р. (in Russian).
Berezhnaya NM, Chekhun VF. Physiological system of conjunctive tissue and oncogenesis. I. Role of cellular components of stroma in tumor development. Oncology 2016; 18 (1): 4–14 (in Russian).
Vasilenko IV, Kondratyuk RB. Parenchymatous-stromal interrelations in tumors and their specifics in stomach cancer of intestinal and diffusive types. Oncology 2006; 8 (1): 7–12 (in Russian).
Friedl P, Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat Rev Mol Cell Biol 2009;
: 445–57.
Alexandrova A.Yu. Evolution of cell interactions with extracellular matrix in carcinogenesis. Biochemistry (Moscow) 2008; 73 (7): 915–24 (in Russian).
Krahmal NV, Zavyalova MV, Denisov EB, et al.Invasion of
tumor epithelial cells: mechanisms and manifestations. Fcna Naturale 2015; 7 (2): 18–30 (in Russian).
Bos R, Zhong H, Colleen F, et al. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst
; 93 (4): 309–14.
Karlsson MC, Gonzalez SF, Welin J, Fuxe J. Epithelialmesenchymal transition in cancer metastasis through the lymphatic system. Mol Oncol 2017; 11 (7): 781–91.
Gwak JM, Kim HJ, Kim EJ, et al. MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer. Breast Cancer Res Treat 2014; 147 (1): 39–49.
Bandyopadhyay S, Mitra R, Maulik U, et al. Development of the human cancer microRNA network. Science 2010; 1: 6. doi: 10.1186/1758–907X-1–6.
Kunej T, Godnic I, Horvat S, et al. Cross talk between microRNA and coding cancer genes. Cancer J 2012; 18 (3): 223–31.
Karamitopoulou E, Haemmig S, Baumgartner U, et al. MicroRNA dysregulation in the tumor microenvironment influences the phenotype of pancreatic cancer. Mod Pathol 2017; 30 (8): 1116–25.
Knudsen KN, Lindebjerg J, Nielsen BS, et al. MicroRNA200b is downregulated in colon cancer budding cells. PLoS One
; 12 (5): e0178564.
Xie N, Wang C, Zhuang Z, et al. Decreased miR-320a promotes invasion and metastasis of tumor budding cells in tongue squamous cell carcinoma. Oncotarget 2016; 7 (40): 65744–57.
Luo D, Wilson GM, Harvel N, et al. A systematic evaluation of miRNA: mRNA interactions involved in the migration
and invasion of breast cancer cells. J Translat Med 2013; 11: 57.
Donnenberg VS, Donnenberg AD, Zimmerlin L, et al. Localization of CD44 and CD90 positive cells to the invasive front
of breast tumors. Cytometry B Clin Cytom 2010; 78 (5): 287–301.
Almendro V, Fuster G. Heterogeneity of breast cancer: etiology and clinical relevance. Clin Transl Oncol 2011; 13 (11): 767–73.
Toole ВР, Hascall VC. Hyaluronan and tumor growth. Am J Pathol 2002; 161 (3): 745–7.
Bourguignon LY, Shiina M, Li JJ. Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression. Adv Cancer Res 2014; 123: 255–75.
Orian-Rousseau V, Sleeman J. CD44 is a multidomain signaling platform that integrates extracellular matrix cues with growth factor and cytokine signals. Adv Cancer Res 2014; 123: 231–54.
Thapa R, Wilson GD. The importance of CD44 as a stem cell biomarker and therapeutic target in cancer. Stem Cells Int 2016; 208: 7204.
Yan Y, Zuo X, Wei D. Concise Review: Emerging role of CD44 in cancer stem cells: a promising biomarker and therapeutic target. Stem Cells Transl Med 2015; 4 (9): 1033–43.
Schwertfeger KL, Cowman MK, Telmer PG, et al. Hyaluronan, inflammation, and breast cancer progression. Front Immunol 2015; 8 (6): 236.
Misra S, Hascall VC, Markwald RR, Ghatak S. Interactions between hyaluronan and its receptors (CD44, rhamm) regulate the activities of inflammation and cancer. Front Immunol 2015; 6 (6): 201.
Palaiologou M, Delladetsima I, Tiniakos D. CD138 (syndecan-1) expression in health and disease. Histol Histopathol
; 29 (2): 177–89.
Gharbaran R. Advances in the molecular functions of syndecan-1 (SDC1/CD138) in the pathogenesis of malignancies. Crit Rev Oncol Hematol 2015; 94 (1): 1–17.
Kurokawa S, Zhang M, Matsumoto S, et al. Reduced syndecan-1 expression (CD138) is correlated with the histological
grade of malignancy at the deep invasive front in oral squamous cell carcinoma. Oral Pathol Med 2006; DOI: 10.1111/j.1600– 0714.2006.00412.x.
Szarvas T, Reis H, Kramer G, et al. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. Hum Pathol 2014; 45 (4): 674–82.
Cousin JM, Cloninger MJ. The Role of Galectin-1 in Cancer Progression, and Synthetic Multivalent Systems for the Study of Galectin-1. Int J Mol Sci 2016; 17 (9): pii: E1566. doi: 10.3390/ijms17091566.
Ito K, Stannard K, Gabutero E, et al. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev 2012; 31 (3–4): 763–78.
Stengel K, Zheng Y. Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell Signalling 2011; 23 (9): 1415–23.
Arias-Romero LE, Chernoff J. Targeting Cdc42 in cancer. Expert Opin Ther Targets 2013; 17 (11): 1263–73.
Ye H, Zhang Y, Geng L, Li Z. Cdc42 expression in cervical cancer and its effects on cervical tumor invasion and migration. Int J Oncol 2015; 46 (2): 757–63.
Sharma M, Sah P, Sharma SS, Radhakrishnan R. Molecular changes in invasive front of oral cancer. J Oral Maxillofac
Pathol 2013; 17 (2): 240–7.
Park SY, Gonen M, Kim HJ, et al. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest 2010; 120: 636–44.
Goswami S, Philippar U, Sun D, et al. Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. Clin Exp Metastasis 2009; 26 (2): 153–9.
Chen W, Delongchamps NB, Mao K, et al. High RhoA expression at the tumor front in clinically localized prostate cancer and association with poor tumor differentiation. Oncol Lett 2016; 11 (2): 1375–81.
Kato K, Kawashiri S, Tanaka A, et al. Predictive value of measuring p53 labeling index at the invasive front of oral squamous cell carcinomas. Pathol Oncol Res 2008; 14: 57–61.
Bos R, Zhong H, Colleen F, et al. Levels of hypoxia-inducible factor-1α during breast carcinogenesis. J Natl Cancer Inst
; 93 (4): 309–14. https://biomolecula.ru/articles/mikrornkumenshaiut-shum-ekspressii-genov.
Rogova LN, Shesrernina NV, Zamechnik TV, et al. Matrix metalloproteinases, their role in physiological and pathological processes (Review). Vestn Novyh Med Technol 2011; 18 (2): 86–92 (in Russian).
Ng CK, Pemberton HN, Reis-Filho JS. Breast cancer intratumor genetic heterogeneity: causes and implications. Expert
Rev Anticancer Ther 2012; 12 (8): 1021–32.
Beca F, Polyak K. Intratumor heterogeneity in breast cancer. Adv Exp Med Biol 2016; 882: 169–89.
Fang Y, Wu J, Wang W, et al. Biologic behavior and longterm outcomes of breast ductal carcinoma in situ with microinvasion. Oncotarget 2016; 27 (39): 64182–90.
Dawson H, Lugli A. Molecular and pathogenetic aspects of tumor budding in colorectal cancer. Front Med (Lausanne) 2015; 10 (2): 11.
Graham RP, Vierkant RA, Tillmans LS, et al. Tumor budding in colorectal carcinoma: confirmation of prognostic significance and histologic cutoff in a population-based cohort. Am J Surg Pathol 2015; 39 (10): 1340–6.
Salhia B, Trippel М, Pfaltz К, Tapia С. High tumor budding stratifies breast cancer with metastatic properties. Breast
Cancer Res Treat 2015; 150 (2). DOI: 10.1007/s10549–015– 3333–3.
Wartenberg M, Centeno I, Haemmig S, et al. PTEN alterations of the stromal cells characterise an aggressive subpopulation of pancreatic cancer with enhanced metastatic potential. Eur J Cancer 2016; 65: 80–90.
Morales-Oyarvide V, Mino-Kenudson M. High-grade lung adenocarcinomas with micropapillary and/or solid patterns: a review. Curr Opin Pulm Med 2014; 20 (4): 317–23.
Koyuncuoglu M, Okyay E, Saatli B, et al. Tumor budding and E-Cadherin expression in endometrial carcinom: Are they prognostic factors in endometrial cancer? Gynecol Oncol 2012; 125: 208–13.
Huang B, Cai J, Xia Xu X, Wang Z. High-grade tumor budding stratifies early-stage cervical cancer with recurrence risk. Plos One 2016; 11 (11): e0166311.
Nowak JA, Agoston A, Zheng Y, et al. Tumor budding is a predictor of nodal metastasis and tumor recurrence in T1 esophageal adenocarcinoma. Mod Pathol 2013; 26: 169A.
Zhang XC, Hashemi SS, Yousefi M, et al. Atypical expression of c-erbB2 in cell clusters overlying focally disrupted breast myoepithelial cell layers: a potential sign for increasing cell motility and invasion. Int J Biol Sci 2008; 4: 259–69.
Khalafalla FG, Khan MW. Inflammation and epithelialmesenchymal transition in pancreatic ductal adenocarcinoma:
fighting against multiple opponents. Cancer Growth Metastasis 2017; doi: 10.1177/1179064417709287. eCollection 2017.
Jiang B,MasonJ, Jewett AA, et al. Cell budding from normal appearing epithelia: a predictor of colorectal cancer metastasis? Int J Biol Sci 2013; 9 (1): 119–33.
Rogers AC, Gibbons D, Hanly AM, et al. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy. Mod Pathol 2014; 27: 156–62.
Graham RP, Vierkant RA, Tillmans LS, et al. Tumor budding in colorectal carcinoma: confirmation of prognostic significance and histologic cutoff in a population-based cohort. Am J Surg Pathol 2015; 39 (10): 1340–6.
Gujam FJA, McMillan DC, Mohammed ZMA, et al. The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer. Br J Cancer 2015; 113: 1066–74.
Yamaguchi Y, Ishii G, Kojima M, et al. Histopathologic features of the tumor budding in adenocarcinoma of the lung. J Thor Oncol 2010; 5 (9): 1361.
Kohler I, Bronsert P, Timme S, et al. Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol 2015; 30 (Suppl 1): 78–84.
Lugli A, Vlajnic T, Giger O, et al. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients. Hum Pathol 2011; 42: 1833–40.
Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol 2009; 33: 134–41.
Guzinska-Ustymowicz K. The role of tumour budding at the front of invasion and recurrence of rectal carcinoma. Anticancer Res 2005; 25 (2B): 1269–72.
Koelzer VH, Zlobec I, Lugli A. Tumor budding in colorectal cancer-ready for diagnostic practice? Hum Pathol 2016; 47
(1): 4–19.
Markl B, Markl M, Schaller T, et al. A new simple morphology-based risk score is prognostic in stage I/II colon cancers. Cancer Med 2016; 5 (7): 1492–501.
Zhang S,Zhang D, Yang Z,Zhang X.Tumor budding, micropapillary pattern, and polyploidy giant cancer cells in colorectal cancer: current status and future prospects. Stem Cells Int 2016; 2016: 4810734. doi: 10.1155/2016/4810734.
Kai K, Aishima S, Aoki S, et al. Cytokeratin immunohistochemistry improves interobserver variability between unskilled pathologists in the evaluation of tumor budding in T1 colorectal cancer. Pathol Int 2016; 66: 75–82.
Zlobec I, Hädrich M, Dawson H, et al. Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients. Br J Cancer 2014; 110: 1008–13.
Max N, Harbaum L, Pollheimer MJ, et al. Tumour budding with and without admixed inflammation: two different sides of the same coin? Br J Cancer 2016; 114 (4): 368–71.
